Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis

Decroo, Tom; Jai, Kya; Aung, Maug; Hossain, M A; Gumusboga, Mourad; Ortuño-Gutiérrez, Nimer; Catherine, Bouke; Jong, Bouke C. de; Deun, Armand Van

doi:10.1183/13993003.02124-2021

Cited by 3 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Introducing bedaquiline [8] throughout the treatment period makes us able to cure the patient, although the duration of the therapy was extended to 5 years.…”

Section: Discussionmentioning

confidence: 99%

Extra-long treatment of MDR-TB osteomyelitis of humerus due to neurotoxicity from the 2nd-line drugs: a case report

2023

View full text Add to dashboard Cite

show abstract

“…Introducing bedaquiline [8] throughout the treatment period makes us able to cure the patient, although the duration of the therapy was extended to 5 years.…”

Section: Discussionmentioning

confidence: 99%

Extra-long treatment of MDR-TB osteomyelitis of humerus due to neurotoxicity from the 2nd-line drugs: a case report

2023

View full text Add to dashboard Cite

show abstract

“… 18 , 21 Recently published data from Bangladesh support the assumption that its early killing effect is too little to sufficiently protect the regimen’s core drug against the development of resistant mutants. 54 Furthermore, Chiang et al . 51 propose to consider the utilization of injectable-containing short MDR-TB regimens again.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, it could be shown that the replacement of the FQ by bedaquiline using the Bangladesh regimen (including the injectable kanamycin) in case of high-level FQ resistance results in higher rates of culture conversion and relapse-free cure, thus demonstrating that bedaquiline but not linezolid can act as core drug for the treatment of patients with FQ-resistant RR-TB. 54 …”

Section: Discussionmentioning

confidence: 99%

Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review

Mallick

Nair

Abbew

et al. 2022

JAC-Antimicrobial Resistance

Self Cite

View full text Add to dashboard Cite

Background Drug-resistant tuberculosis (DR-TB) is considered to be a public health threat and is difficult to cure, requiring a lengthy treatment with potent, potentially toxic drugs. The novel antimicrobial agent bedaquiline has shown promising results for patients with DR-TB, improving the rate of culture conversion and reducing TB-related mortality. However, increasing numbers of cases with acquired bedaquiline resistance (ABR) have been reported in recent years. Methods This systematic review aimed to assess the frequency of ABR and characteristics of patients acquiring it. Studies showing data on sequential bedaquiline drug-susceptibility testing in patients treated with a bedaquiline-containing regimen were included. The databases CENTRAL, PubMed and Embase were manually searched, and 866 unique records identified, eventually leading to the inclusion of 13 studies. Phenotypic ABR was assessed based on predefined MIC thresholds and genotypic ABR based on the emergence of resistance-associated variants. Results The median (IQR) frequency of phenotypic ABR was 2.2% (1.1%–4.6%) and 4.4% (1.8%–5.8%) for genotypic ABR. Among the studies reporting individual data of patients with ABR, the median number of likely effective drugs in a treatment regimen was five, in accordance with WHO recommendations. In regard to the utilization of important companion drugs with high and early bactericidal activity, linezolid was included in the regimen of most ABR patients, whereas the usage of other group A (fluoroquinolones) and former group B drugs (second-line injectable drugs) was rare. Conclusions Our findings suggest a relevant frequency of ABR, urging for a better protection against it. Therefore, treatment regimens should include drugs with high resistance-preventing capacity through high and early bactericidal activity.

show abstract

“…DECROO et al [13] added to the body of knowledge how to manage the treatment of TB resistant to the most important first-line anti-TB drug, rifampicin, when resistance to fluoroquinolones is unknown. Given the complexity of describing details of the regimens evaluated in a short editorial, we invite the interested reader to read the manuscript.…”

Section: Tb Diagnosismentioning

confidence: 99%

Commemorating World Tuberculosis Day 2022: recentERJarticles of critical relevance to ending TB and saving lives

et al. 2022

View full text Add to dashboard Cite

show abstract

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis

Abstract: Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis.

Cited by 3 publications

References 12 publications

Extra-long treatment of MDR-TB osteomyelitis of humerus due to neurotoxicity from the 2nd-line drugs: a case report

Extra-long treatment of MDR-TB osteomyelitis of humerus due to neurotoxicity from the 2nd-line drugs: a case report

Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review

Commemorating World Tuberculosis Day 2022: recentERJarticles of critical relevance to ending TB and saving lives

Contact Info

Product

Resources

About